Back to top

Top Ranked Momentum Stocks to Buy for November 23rd

Read MoreHide Full Article

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 23rd:

Arbutus Biopharma Corporation (ABUS - Free Report) : This owner and operator of a biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.7% over the last 60 days.

Arbutus Biopharma Corporation Price and Consensus

Arbutus’ shares gained 13.6% over the last one month more than S&P 500’s loss of -0.2%. The company possesses a Momentum Score of A.

Arbutus Biopharma Corporation Price

Opexa Therapeutics, Inc. (ACER - Free Report) : This owner and operator of a pharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 4.5% over the last 60 days.

Opexa Therapeutics, Inc. Price and Consensus

ACI’s shares gained 6.5% over the last one month. The company possesses a Momentum Score of A.

Opexa Therapeutics, Inc. Price

Ameren Corporation (AEE - Free Report) : This owner and operator of a public utility holding company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.7% over the last 60 days.

Ameren Corporation Price and Consensus

Ameren’s shares gained 1.1% over the last one month. The company possesses a Momentum Score of B.

Ameren Corporation Price

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Ameren Corporation (AEE) - free report >>

Opexa Therapeutics, Inc. (ACER) - free report >>

Arbutus Biopharma Corporation (ABUS) - free report >>

More from Zacks Zacks #1 Rank Additions

You May Like

Published in